Skip to content

Can ELABELA induce monozygotic twinning?

Can ELABELA induce monozygotic twinning? - ELABELA in MZ twinning

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON46173
Enrollment
280
Registered
2019-01-08
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

monozygotic twins

Interventions

None listed

Sponsors

Vrije Universiteit Medisch Centrum
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Good quality embryos: According to standard laboratory protocol embryo transfer takes place on day 3 and surplus embryos are assessed again for developmental progression on day 4, day 5 and day 6. If the quality of the spare embryos is sufficient they are cryopreserved on day 4, day 5 or day 6. Embryos are considered for cryopreservation if the following criteria are met: * Proof of fertilization: 2 pro-nuclei * Regular development from day 1 to day 3 * Satisfactory embryo quality determined in terms of o Number of blastomeres: morula on day 4, beginning of compaction on day 5 and blastocyst (B3) on day 6. o Degree of fragmentation: maximal 20% Only donated embryos of sufficient morphological quality after thawing will be considered for the study. The embryos have to fulfil the following criteria directly after thawing o Minimum number of blastomeres: 8 cells o Maximum degree of fragmentation: 20% o Maximum degree of atresia: 25%

Exclusion criteria

Exclusion criteria: A varying percentage of cell death (atresia) and developmental regression in thawed embryos is observed regularly. Therefore, embryos with insufficient morphological quality after thawing will be excluded from the study as described in the inclusion criteria.

Design outcomes

Primary

MeasureTime frame
The main study parameter is the observation in at least 50% of the embryos treated with exogenous ELABELA, followed by characterization, of postzygotic splitting/duplication of the ICM compared to the control group (average MZ twinning percentage ~2%).

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)